To view the PDF file, sign up for a MySharenet subscription.

ASCENDIS HEALTH LIMITED - Trading Update

Release Date: 20/12/2019 07:05
Code(s): ASC     PDF:  
 
Wrap Text
Trading Update

 Ascendis Health Limited
 (Registration number 2008/005856/06)
 (Incorporated in the Republic of South Africa)
 Share code: ASC
 ISIN: ZAE000185005
 (“Ascendis Health” or “the Company”)

Trading Update

The board of directors (“the Board”) wishes to provide an update to the Ascendis Health shareholders on the
performance of its Remedica pharmaceutical business unit in Cyprus (“Remedica”) for the 12 months ended
30 November 2019 (“the Current Period”) versus the 12 months ended 30 November 2018 (“the Prior Period”).

Remedica forms a material part of the Company’s de-gearing strategy and continues to perform well and in line with
management’s expectations. For the Current Period, Remedica delivered revenue growth of 18.7%, and growth in
normalised earnings before interest, tax, depreciation and amortisation (“EBITDA”) of 21.3% from the Prior Period.

The growth in revenue and normalised EBITDA in comparison to the Prior Period is driven by the launch of products in
new markets and the improvement in raw material supply.

Shareholders are advised that normalised EBITDA is not a term defined by International Financial Reporting Standards
and may accordingly differ from company to company. The Board however believes that EBITDA is a relevant
performance measure as it provides a measure of cash earnings.

The normalised EBITDA figure for Remedica has been calculated consistently with Ascendis Health’s methodology for
the calculation of normalised EBITDA as set out in its latest annual report.

The financial information on which this trading update is based has not been reviewed or reported on by the
Company’s external auditors. The Board is responsible for the preparation of the performance measures and ensuring
its compliance with the JSE Listings Requirements.

The Company expects to release a further voluntary trading update in early February 2020, wherein Ascendis Health
shareholders will be provided with further information on the Ascendis group performance.


20 December 2019
Bryanston

Sponsor
Questco Corporate Advisory Proprietary Limited

Date: 20-12-2019 07:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story